Business, Healthcare

European Commission approves KEYTRUDA® (pembrolizumab) as first-line treatment in adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer

KEYTRUDA Is First Checkpoint Inhibitor Approved in Europe to Treat MSI-H or dMMR Colorectal Cancer European Approval Based on Results From KEYNOTE-177 Trial Demonstrating KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 40% Compared With Chemotherapy KENILWORTH, N.J. — (BUSINESS

Business, Healthcare

AdvanSix furthers commitment to sulfur nutrition

Expands Focus on Sulfur Nutrition for Wide Variety of Crops Including Soybeans Robust Operational Performance Supports Improved Granular Conversion Acquires Certain Assets of Commonwealth Industrial Services (CIS), Adding Packaging, Warehousing and Logistics Capabilities PARSIPPANY, N.J. & HOPEWELL, Va. — (BUSINESS WIRE) —

Business, Healthcare, Local News

U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma

In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced